Show simple item record

dc.contributor.authorWest, Catharine M Len
dc.contributor.authorReeves, S Jen
dc.contributor.authorBrough, Wen
dc.date.accessioned2010-08-18T09:22:55Z
dc.date.available2010-08-18T09:22:55Z
dc.date.issued1990-12-03
dc.identifier.citationAdditive interaction between tamoxifen and rifampicin in human biliary tract carcinoma cells. 1990, 55 (2):159-63 Cancer Lett.en
dc.identifier.issn0304-3835
dc.identifier.pmid2265416
dc.identifier.doi10.1016/0304-3835(90)90027-U
dc.identifier.urihttp://hdl.handle.net/10541/109809
dc.description.abstractA novel two-drug combination of tamoxifen and rifampicin has been investigated for the treatment of biliary tract-associated malignancies. Their effects, alone and in combination, on human tumour cells were studied using two pancreatic carcinoma cell lines. MIA PaCa-2 and AsPC-1, and a gall bladder carcinoma cell line, G-415. Inhibition of growth was used as an endpoint. The cells differed in sensitivity to equimolar doses of the two drugs given as single agents. Combined doses of rifampicin and tamoxifen resulted in growth inhibition to an extent that was suggestive of additive or synergistic drug effects. More detailed analysis was carried out, involving the production of an 'envelope of additivity' for each cell line. An additive effect of drug combination was shown to occur in all three cell lines, thus providing a basis for use of this novel two-drug combination in the treatment of biliary tract-associated malignancies.
dc.language.isoenen
dc.subjectBiliary Tract Canceren
dc.subjectGallbladder Canceren
dc.subjectPancreatic Canceren
dc.subjectCultured Tumour Cellsen
dc.subject.meshBiliary Tract Neoplasms
dc.subject.meshCell Division
dc.subject.meshDrug Interactions
dc.subject.meshDrug Synergism
dc.subject.meshDrug Therapy, Combination
dc.subject.meshGallbladder Neoplasms
dc.subject.meshHumans
dc.subject.meshPancreatic Neoplasms
dc.subject.meshRifampin
dc.subject.meshTamoxifen
dc.subject.meshTumor Cells, Cultured
dc.titleAdditive interaction between tamoxifen and rifampicin in human biliary tract carcinoma cells.en
dc.typeArticleen
dc.contributor.departmentDepartment of Radiobiology, Paterson Institute for Cancer Research, Manchester, U.K.en
dc.identifier.journalCancer Lettersen
html.description.abstractA novel two-drug combination of tamoxifen and rifampicin has been investigated for the treatment of biliary tract-associated malignancies. Their effects, alone and in combination, on human tumour cells were studied using two pancreatic carcinoma cell lines. MIA PaCa-2 and AsPC-1, and a gall bladder carcinoma cell line, G-415. Inhibition of growth was used as an endpoint. The cells differed in sensitivity to equimolar doses of the two drugs given as single agents. Combined doses of rifampicin and tamoxifen resulted in growth inhibition to an extent that was suggestive of additive or synergistic drug effects. More detailed analysis was carried out, involving the production of an 'envelope of additivity' for each cell line. An additive effect of drug combination was shown to occur in all three cell lines, thus providing a basis for use of this novel two-drug combination in the treatment of biliary tract-associated malignancies.


Files in this item

This item appears in the following Collection(s)

Show simple item record